CAR-T therapies are set to revolutionise cancer treatment. With first curative therapies gaining market access across the globe, CAR-T therapies are subject to numerous commercial and non-commercial challenges. Christian Zuberer and Maximilian Feld of Homburg & Partner analyse how, despite positive clinical responses, the ability to overcome these challenges will determine the future of CAR-T therapies and show whether pharmaceutical companies can make true on the promise of initiating a new era of cancer care.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/07/Go-to-market-Challenges-of-CAR-T-Therapies.pdf”]